Introduction {#sec1}
============

Nucleoside analogs such as acyclovir, a broad acting antiviral, are useful for the prevention and treatment of sexually transmitted diseases caused by viruses, especially those residing in cells. Treatment of intracellular viruses depends on antiviral drugs being carried across cell membranes and accumulating within the cells. Transporters such as the human concentrative nucleoside transporter, CNT3 (a product of the *SLC28A3* gene) play an important role in carrying nucleosides and their analogs into cells.

Epithelial cells host a variety of transporters that typically exhibit concentrative carriers at the apical side, and equilibrative carriers located at the basolateral membrane, allowing coupling to occur, permitting the absorption or elimination of solutes.^[@ref1]^ CNT3 transporters mediate the transport of both purine and pyrimidine nucleosides, and they are involved in adenosine signaling regulation at the cellular level. The CNT3 protein has important roles in drug delivery, subsequent drug tissue distribution, and, hence, efficacy because of its ability to absorb, distribute, and eliminate drugs.^[@ref2]−[@ref4]^

While the expression of transporter proteins within various epithelial tissues is well-known,^[@ref5]−[@ref7]^ information on drug transporters in vaginal epithelial cells (VEC) remains scarce. Better comprehension of the abundance and localization of different drug transporters is critical for the development of efficient antimicrobial and antiviral drug delivery methods for women, which are dependent on adequate drug absorption and distribution within the vaginal epithelium. Additionally, drug delivery systems, such as vaginal rings, are utilized worldwide for birth control, and more recently, pre-exposure prophylaxis (PrEP). Research that reveals the locations and exact mechanisms of drug transporter function is critical for efficient drug absorptions among vaginal ring users. The advancement of drug development depends on the optimization of various nucleoside analogs.

The aim of this study is to develop an approach for determining the location of drug transporters in VEC using microscopy and commercial antibodies. Comparisons between results obtained by light and electron microscopy using antibodies to CNT3, an uptake sodium-coupled nucleoside transporter abundant in epithelium,^[@ref8]^ is presented. The approach, using a combination of immunocytochemical and quantitative methods, will assist in validating antibodies with general availability, and form the basis of detailed studies of transporter proteins in VEC and other cell types.

Results {#sec2}
=======

The anti-CNT3 antibodies label agarose-embedded VEC with a minimal nonspecific label ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}). On some VEC, the fluorescent signal was located on one region of the cell membrane ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}), with intracellular punctate labeling ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}). Although the cells labeled with the antibodies, the CLSM imaging did not easily reveal any identifiable structural specificity within or on the cells, perhaps because of the scraped cells being distorted during preparation.

![CLSM of VEC labeled with anti-CNT3 antibodies. Legend: VEC from a Caucasian female in her mid 30s (037) were labeled with antibodies to the CNT3 SLC28A3 transporter protein. The cells were also labeled with concanavalin A and DAPI to visualize the cells. (A) Concanavalin A label (green); (B) CNT3 label (red); (C) DAPI label (blue); (D) Overlay image of all fluorescent signals. The anti-CNT3 antibody shows more intense label on one side of the VEC (arrow). Intracellular punctate anti-CNT3 label is present. Scale bar = 20 μm.](ao0c02329_0002){#fig1}

The cytoplasmic location of the binding site of the anti-CNT3 antibody was confirmed by comparing CNT3 labeling on cells, which had not been treated with Triton X-100, with cells that had been treated with the detergent. Triton X-100 opens the membranes of aldehyde-fixed cells giving antibodies access to intracellular sites. As expected, cells not treated with Triton X-100 had only low levels of CNT3 labeling ([Figure S1A](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c02329/suppl_file/ao0c02329_si_001.pdf)), while treated cells labeled with the anti-CNT3 antibodies ([Figure S1B](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c02329/suppl_file/ao0c02329_si_001.pdf)).

Thin sections through VEC prepared for electron microscopy were labeled with specific anti-CNT3 antibodies. Antibody binding on the sections was visualized using particulate protein A-gold particles (PAG10) on thin sections. The PAG10 label, indicating CNT3 binding, was associated with microvilli ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}) located on one face of the VEC ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"} and [Figure S2](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c02329/suppl_file/ao0c02329_si_001.pdf)). The microvilli had a diameter of approximately 100 nm ([Figure S2B](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c02329/suppl_file/ao0c02329_si_001.pdf)). In addition to being present over the inner part of microvilli, the antibody labeling occurred in low frequency over the cell plasma membrane, cytoplasm, unidentified cytoplasmic structures, and intracellular cytokeratin bundles. The cytoplasmic structures, which were labeled, could not be identified as specific structures, but they all appeared to be membrane-bound vesicles.

![Transmission electron microscopy of VECs labeled with anti-CNT3 antibodies. Legend: A thin section through a VEC from volunteer OCIS-02A-037, labeled with anti-CNT3 antibodies and PAG10. (A) Low magnification of part of an epithelial cell showing well-developed microvilli on one side of the cell. There are few intracellular organelles. Scale bar = 2 μm. (B) Details of the cell from panel (A), indicated by a box. The PAG10 particles (arrows) are located on the microvilli. Scale bar = 200 nm. (C) Details of the cell from panel (A), indicated by a box. One PAG10 particle (arrow) is present on the luminal side of the membrane of an unidentified intracellular structure. Scale bar = 200 nm.](ao0c02329_0003){#fig2}

Sections labeled with the anti-CNT3 antibodies and PAG10 were used to count the numbers of PAG10 particles observed over each identified compartment. Using a surveying protocol, we were able to show that between 40 and 60% of the gold particles on the sections were found over VEC microvilli profiles. Smaller numbers of PAG10 particles were found over the cell plasma membrane, cytoplasm, unidentified cytoplasmic structures, and intracellular cytokeratin bundles. The number of gold particles counted over support film ("background"), in regions where there were no sections, was in the same range as the numbers of PAG10 particles over the cytokeratin bundles. Plasma membrane, cytoplasm, and unidentified cytoplasmic structures all had numbers of associated PAG10 particles that were slightly above nonspecific labeling ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"} and [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). No label was detected over nuclear profiles or mitochondria (data not shown).

![Distribution of the CNT3 label over cellular structures by counting PAG10 particles with transmission electron microscopy. Legend: The recognizable subcellular structure where PAG10 particles were attached to on thin sections of VEC were scored and expressed as a percentage of the total. A section on each of 4 grids was examined, with two grids being labeled simultaneously. Specific label appears to be associated with microvilli, the plasma membrane, and with the cell cytoplasm.](ao0c02329_0004){#fig3}

###### PAG10 Particle Counts and Data Used for Calculating the Pearson Correlation coefficient[a](#t1fn1){ref-type="table-fn"}

                          grid 1 (*x*)   grid 2 (*y*)   *x*^2^   *y*^2^   *xy*
  ----------------------- -------------- -------------- -------- -------- --------
  plasma membrane         43             40             1849     1600     1720
  keratin                 1              18             1        324      18
  cytoplasm               2              14             4        196      28
  microvilli              134            120            17,956   14,400   16,080
  unknown intracellular   17             18             289      324      306
  background              9              24             81       576      216
  sums (∑)                206            234            42,436   54,756   48,204

                          grid 3 (*x*)   grid 4 (*y*)   *x*^2^   *y*^2^   *xy*
  ----------------------- -------------- -------------- -------- -------- --------
  plasma membrane         19             16             361      256      304
  keratin                 9              24             81       576      216
  cytoplasm               27             36             729      1296     972
  microvilli              111            77             12,321   5929     8547
  unknown intracellular   30             28             900      784      840
  background              10             31             100      961      310
  sums (∑)                206            212            14,492   9802     11,189

Raw data of PAG10 particle counts from sections on four different specimen grids. Grids 1 and grid 2 were labeled together. Grid 3 and grid 4 were labeled together but on a different day. The table shows the number of PAG10 particles found over each identifiable structure on the sections. Columns labeled "*x*^2^, *y*^2^ and *xy*" show the data from grids 1 (*x*) and 2 (*y*) processed for calculating the Pearson correlation coefficient ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}).

Comparing the PAG10 counts on sections from two separate grids labeled simultaneously with anti-CNT3 and PAG10 provided raw data ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}), which was used to obtain the Pearson correlation coefficient (*r*) between the grids. The *r* value for comparing the labeling on grids 1 and 2 was 0.99 (95% CI: 0.918--0.991), *p* = 0.0001), and the *r* value for grids 3 and 4 was 0.94 (95% CI: 0.549--0.994, *p* = 0.0051) (listed on [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). The probability of the distribution of labeling being uniform is \<0.0001 for all comparisons, by the χ^2^ test suggesting that there is a systematic labeling. The proportion of gold particles on microvilli is much greater than expected if the distribution were random.

###### Pearson Correlation Coefficients (*r*), Showing the Degree of Agreement between Gold Label on Different Grids[a](#t2fn1){ref-type="table-fn"}

  grid \#   grid \#   *r*-value   95% Cl         *p*      Spearman's ρ
  --------- --------- ----------- -------------- -------- ---------------------
  1         2         0.99        0.918--0.991   0.0001   0.81, *p* = 0.0498
  3         4         0.94        0.56--0.994    0.0046   0.6, *p* = 0.2417
  1         3         0.94        0.549--0.997   0.0051   0.714, *p* = 0.1361
  1         4         0.83        0.062--0.981   0.04     0.2, *p* = 0.714
  2         3         0.94        0.53--0.993    0.0055   0.26, *p* = 0.618
  2         4         0.87        0.187--0.985   0.0253   0.06, *p* = 0.91

The Pearson correlation coefficients of PAG10 labeling for pairs of grids show close correlation between sections on grids labeled on the same day (grids 1 and 2 or 3 and 4), and between grids labeled on different days. Lower correlation coefficients were observed between grids labeled on different days (grids 1 and 4 or 2 and 4), which had *r* values of 0.83 and 0.87, respectively. For both the Pearson correlation and Spearman's ρ, the closer *r* is to 1 the better the agreement in the gold label distribution. See Lucocq et al.^[@ref9]^ for more details on how the calculations were performed.

Closer examination of the labeling pattern on the CNT3-labeled cells showed the cells had a polarity. Labeling was concentrated over microvilli on one part of the cell. The unlabeled parts of the cells also lacked microvilli ([Figure S2](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c02329/suppl_file/ao0c02329_si_001.pdf)). When the PAG10 particles were quantified using cross-lattice overlays, the association with microvilli was further supported ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}). The number of gold particles on the plasma membrane of apical regions (identified by the presence of microvilli) were higher than the numbers of gold particles on the plasma membrane of basolateral surfaces (with reduced numbers of microvilli) ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}). The number of PAG10 particles over microvilli on the apical surface was also higher than the PAG10 on microvilli on the basolateral surfaces ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}). PAG10 particles closer than 3 nm to the membrane were counted, as were the gold particles 3--5 nm distant from the membrane ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}). On apical microvilli, the PAG10 particles were equally distributed between being close to the membrane (\<3 nm) and being 3--5 nm away from the membrane ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}). Apical plasma membrane labeling was mostly 3 nm or less from the membrane ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}).

![PAG10 particle quantification over membranes. Legend: PAG10 labeling per micron length of membrane, estimated using cross lattice overlays, show increased amounts of gold over microvilli on one side of anti-CNT3-labeled human VEC. Apical: (A1) gold particles over plasma membrane less than \<3 nm from the membrane. (A2) Gold particles over plasma membrane between 3 and 5 nm from the membrane. (A3) Gold particles over microvilli less than \<3 nm from the membrane. (A4) Gold particles over microvilli between 3 and 5 nm from the membrane. Basolateral: (B1) gold particles over plasma membrane less than \<3 nm from the membrane. (B2) Gold particles over plasma membrane between 3 and 5 nm from the membrane. (B3) Gold particles over microvilli less than \<3 nm from the membrane. (B4) Gold particles over microvilli between 3 and 5 nm from the membrane.](ao0c02329_0005){#fig4}

The anti-CNT3 labeling was not distributed uniformly over the microvilli. While the mean microvilli labeling was 8 gold particles per μm length ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}), this estimate may be low because of the presence of microvilli on the apical surface with few PAG10 particles. The heterogeneous labeling pattern of microvilli was demonstrated by comparing similar membrane zones on sequential sections of individual cells. The same CNT3 labeled regions on microvilli showed a high frequency of label over microvilli in one section ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"} and [Figure S3](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c02329/suppl_file/ao0c02329_si_001.pdf)) but reduced labeling on the sequential section ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"} and [Figure S3](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c02329/suppl_file/ao0c02329_si_001.pdf)), even though both sections were mounted on the same specimen grid and labeled together.

![Sequential sections through human VEC labeled with anti-CNT3 antibodies. Legend: Two sequential sections through VEC from an African American female in her mid 30s (OCIS-02A-025) labeled with anti-CNT3 antibodies and protein A-gold. The 60 nm thick sections, 180 nm apart, show antibody labeling over the same region of one cell. The variability of antibody labeling is highlighted by comparing labeling over the same region of one cell in two sequential sections. (A,B) Low magnification images of the same cell 180 nm apart. The boxes highlight the region magnified in figures (C,D). Scale bar = 5 μm. (C,D) High magnification images of labeled microvilli on the highlighted part of the cell. The microvilli in panel C have more CNT3 label than the microvilli in panel (D). Extracellular bacteria (b) were useful for orientation. Scale = 0.5 μm.](ao0c02329_0006){#fig5}

Finally, in order to confirm the PAG10 labeling on sections was due to specific CNT3 binding and not due to protein A binding to cells, a PAG10 control experiment was performed. Two adjacent serial sections, each 60 nm thick, were mounted on grids and labeled. One was labeled with anti-CNT3 and PAG10. The other section was only labeled with PAG10. Each section was imaged and similar regions on identical cells were compared ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}). The CNT3 antibodies labeled membranes, microvilli, and intracellular membranes ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}A,C). Gold particles were not detected over the same structures on sections labeled only with the PAG10 ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}B,D).

![Protein A-gold control. Legend: Two serial sections (adjacent 60 nm sections) through VEC from an African American female in her mid 30s (OCIS-02A-025). The sections were placed on separate grids and labeled with CNT3 antibodies and PAG10 (A,C) or with PAG10 only (B,D). The same cells were located and imaged for comparison. (A) Anti-CNT3 labeling, indicated by the presence of gold particles (arrows), is associated with the plasma membrane. Some gold particles are present on the cell cytoplasm. An extracellular bacterium (b) helped with identifying the cell. (C) Anti-CNT3 label is present over intracellular structures. (B) The same cell in a serial section was incubated only with PAG10 and showed no gold particles over the cell membrane or cytoplasm. (D) An intracellular structure, which labeled with anti-CNT3, did not label with PAG10. Scale bars = 0.5 μm.](ao0c02329_0007){#fig6}

Discussion {#sec3}
==========

The CNT3 drug transporter protein was located on the microvilli of VECs using high-resolution immunolabeling. The CNT3 protein is a member of the solute carrier (SLC) transporters, and is primarily involved with carrying purine and pyrimidine nucleosides across biological membranes. The CNT3 protein can carry nucleoside analogs used in antiretroviral treatments across membranes, so has the potential to affect drug efficacy.

The aim of this work was to test a method for locating the human concentrative nucleoside transporter CNT3 in or on VEC from female volunteers. The VEC, from a healthy Caucasian volunteer in her mid 30s, were immunolabeled with a commercial antibody, which has previously been used to identify CNT3 in human pancreatic cancer cells by western blotting and immunofluorescence microscopy.^[@ref10]−[@ref12]^ Here, we show CNT3 is present on VEC, with a concentration of label over microvilli on one face of the cells. A second quantitative analysis was performed on VEC from an African America female. Cross lattice overlays on a random series of images were used to to determine the PAG10 particle density on the two different regions of labeled cells. The membranes with PAG10-positive microvilli were designated "apical", and membranes without microvilli were designated "basolateral", consistent with other reports that CNT proteins are restricted to apical regions of polarized cells.^[@ref1],[@ref13]−[@ref15]^ The CNT3 labeling on cells from the two females were similar, with most of the PAG10 being detected on microvilli.

By light microscopy, labeling experiments using the polyclonal anti-CNT3 antibodies were able to confirm that binding to the human VEC occurred. However, limitations of specimen resolution restricted the ability to obtain other labeling information. The poor morphology, or distortion, was most probably due to the way the cells were prepared. Centrifugation followed by agarose embedding caused the cells to round up making them difficult to image. However, subsequent high-resolution imaging showed the anti-CNT3 antibody was specifically labeling of microvilli. The specific labeling of the microvilli was confirmed by unbiased PAG10 particle counts on sections from four specimen grids. Specific labeling of VEC plasma membrane was also suggested by the results obtained from two of the grids examined. However, anti-CNT3 labeling on two other grids did not support any specific labeling of the plasma membrane. Although the inconsistent labeling observed on different days may be due to inconsistent antibody dilutions, it is more likely that the differences were due to the heterogeneous expression of the CNT3 protein on the cell membranes. Not only was the label predominantly located on the apical membrane, but it was concentrated in specific regions. While some microvilli strongly labeled, other microvilli in close proximity had reduced labeling.

Labeling of keratin fibers, cell cytoplasm, and other unknown, or unidentified, intracellular structures were at similar levels to the labeling density of support film on all four grids. The location of the CNT3 protein on the microvilli and the plasma membrane is ideal for carrying target molecules into or out of cells. The CNT3 protein must still be in an active state to carry out its function, a condition that is not yet confirmed in freshly shed human VEC.

The initial sampling and quantitative approach applied to evaluating antibody labeling distribution was chosen because it is rapid, unbiased and simple to understand and carry out. Labeled sections are scanned to identify gold particles, the location of which is scored on a panel of predetermined subcellular structures. The collected data can be displayed on a bar chart using either the raw data, or as were presented here, as percentages of the total number of gold particles counted. The results represent observed frequency of labeling over the different subcellular compartments. By labeling two grids in tandem and scoring the labeling patterns independently, we were able to test for correlations between the distributions of gold counts between individual grids of the same labeling experiment. By repeating the labeling on two other grids, we were able to test labeling correlations on grids from different experiments. In all instances, when the Pearson correlation coefficient (*r*) for each pair was calculated, it was close to 1. The closer the *r* value is to 1, the better the agreement in the gold label distribution, which supports the initial observation that the anti-CNT3 antibody labeled microvilli on human VEC. Similarly, the χ^2^ tests suggest that the labeling is systematic and not random.

One disadvantage of performing the rapid scanning approach for gold particle counting is its inability to provide reliable estimates of the labeling density over subcellular structures. However, by using cross-lattice overlays on micrographs, it is possible to estimate the amounts of PAG10 particles over the membranes. The PAG10 particles being counted had two locations within the microvilli, either they were close to the outer membrane (≤3 nm) or were between 3 and 5 nm away from the membrane. The counting produced an estimate of 15 PAG10 particles per μm of microvillus membrane (8 PAG10 particles \<3 nm from membrane and 7 that were 3−5 nm distance from the microvilli membrane), suggesting a high number of CNT3 molecules present on each structure. The peptide sequence recognized by the CNT3 antibodies is cytoplasmic so labeling of the cytoplasmic regions of the membranes was to be expected. PAG10 particles labeling far from the membrane can be explained if the microvilli are tubular in shape. Calibrated micrographs show the microvilli to have average diameters of approximately 100 nm. The section thickness is only 60 nm, so it is possible that on many sections, the inner parts of the microvilli are also close to the outer membrane. This speculation is supported by the labeling associated with the plasma membrane being mostly \<3 nm from the membrane, a result of the plasma membrane profile being perpendicular to the plane of sectioning.

Using a commercial antibody to locate a membrane protein at high-resolution on VEC is seldom performed, most likely because of the limited availability of skills using this approach. By combining the high-resolution imaging with a particulate visualization marker such as a colloidal gold probe, antibody labeling could be quantified and tested for specificity. The antibody used to locate the CNT3 protein did not produce sufficient information at the light microscope level to determine a specific location within VEC. Electron microscopy was able to locate the CNT3 protein on microvilli on the cells, and thus assist in determining possible functional mechanisms for the protein within the cells.

Immunolabeling relies heavily on the quality of reagents being used. The most variable and unreliable of these reagents is the primary antibody that is chosen for use.^[@ref16]−[@ref18]^ Other than providing details of the antigen being used to generate the antibody, commercial antibodies are sold with minimal validation. The antibody used in this study has minimal validation studies, which were performed on cells and tissues other than VEC. In addition to identifying the apical microvilli as the primary site for CNT3 expression in VEC, we have also obtained further characterization of these antibodies. A cytoplasmic location for the antigen being recognized by the CNT3 antibodies was confirmed when the antibodies were used to label undisrupted cells. Only cells permeabilized by Triton X-100 would label with the antibodies. The PAG10 used in this study was also confirmed to not bind to the human VEC, indicating the presence of PAG10 on sections being due to specific CNT3 antibody binding. Using serial sections to compare the same region of cell, one labeled with antibody and PAG10 and the other labeled only with PAG10 is a powerful way of confirming the specificity of CNT3 labeling.

Conclusions {#sec4}
===========

The human concentrative nucleoside transporter CNT3 mediates the unidirectional flow of nucleosides, preferring pyrimidine and purine nucleosides.^[@ref19]^ The broad selectivity of this protein gives it the ability to translocate nucleoside-derived anticancer and antiviral drugs.^[@ref19]^ Using high resolution imaging, the CNT3 transporter was located in the microvilli of VEC from two female volunteers, one Caucasian and one African American. Identifying human transporters on human VEC is relevant when studying normal physiological processes, and when preventing sexually transmitted infections. The transporters play important roles in moving nucleosides and nucleotides, important modulators of nutrient uptake and maintenance of cellular homeostasis, across cell membranes. The specificity of these transporters is not strictly restricted to their respective substrates, so nucleoside analog drugs with significant structural similarity to the physiological substrates have the potential to be recognized and transported by these transporters. Many of the drugs used to treat viral infections are nucleoside and nucleotide analogs, which can interact with the transporter proteins, and be carried across membranes.

Experimental Section {#sec5}
====================

Cell Collection {#sec5.1}
---------------

Ethical approval for the involvement of women in this study was consented by the Aspire Institutional Review Board (project \#OCIS-02, approved on 07/10/2017). Written informed consent was obtained from all volunteers, and guidelines and policies established by the World Health Organization for good clinical practice and Aspire IRB were followed. Female volunteers were recruited to submit to a self-sampling protocol, where VEC were collected using a menstrual soft cup.^[@ref20]^ VEC were removed from the soft cup by centrifugation, fixed in 4% formalin in 100 mM phosphate buffer and stored at 4 °C until used. The cells used in this validation study were from two randomly selected females: OCIS-02A-037, a healthy Caucasian, and OCIS-02A-025, an African American. Both volunteers were in their mid 30s.

Cultured Cells {#sec5.2}
--------------

Human immortalized VEC (V19 cells)^[@ref21],[@ref22]^ were propagated in an antibiotic-free, keratinocyte serum-free medium (KSFM; Invitrogen, Carlsbad CA) in plastic flasks or in tissue culture dishes containing sterile, 12 mm diameter round coverslips. The cells were incubated overnight at 37 °C in 5% CO~2~ in a humidified incubator. Cells were fixed in 4% formalin in 100 mM phosphate buffer and stored at 4 °C until used.

Immunocytochemistry {#sec5.3}
-------------------

For light microscopy fixed VEC were pelleted and resuspended in low melting point agarose maintained at 40 °C. The VEC suspended in agarose were pressed flat between two parafilm-coated glass slides, placed on ice and allowed to gel. Small pieces of agarose with embedded VEC were removed for immunolabeling.

V19 cultured cells were washed to remove aldehyde and either labeled intact or labeled after permeabilization by 1% Triton X-100 (Sigma-Aldrich).

All cells were immunolabeled with the anti-CNT3 antibodies (Atlas Antibodies: rabbit antihuman CNT3 polyclonal, \#HPA023311) and fluorescent secondary antibodies \[Abcam: goat anti-rabbit IgG H&L (Cy5) pre-adsorbed (ab6564)\]. The anti-CNT3 antibodies were prepared and affinity purified using the recombinant protein epitope signature tag (PrEST) antigen sequence: MELRSTAAPRAEGYSNVGFQNEENFLENENTSGNNSIRSRAVQSREHTNTKQDEEQVTVEQDSPRNREHMEDDDEEMQQKGCLERRYDTVCGFCRKHKTTLRH. The sequence lies between positions 465 and 479 of the *SLC28A3* gene, encoding a cytoplasmic region of the protein.^[@ref23]−[@ref26]^

Immunolabeling followed an established protocol.^[@ref27]^ The embedded VEC were washed with phosphate buffered saline (PBS), washed with PBS containing 0.15% glycine, permeabilized by 0.1% Triton X-100 in PBS for 10 min, treated with 1% bovine serum albumin (BSA) in PBS, and incubated overnight in anti-CNT-3 antibodies diluted 1:100 in PBS--BSA. The VEC were then washed with PBS, treated with PBS--BSA and incubated with fluorescent secondary antibody also diluted 1:100 in PBS--BSA. The VEC were labeled with DAPI (4′,6-diamidino-2-phenylindole)^[@ref28]^ and fluorescent concanavalin A to visualize the cells. The labeled VEC in agarose were mounted on glass slides in Mowiol containing DABCO (1,4-diazabicyclo\[2.2.2\]octane).^[@ref29]−[@ref31]^ Labeled cells were imaged by confocal laser scanning microscopy (Zeiss LSM 510-Meta, Carl Zeiss AG, Oberkochen, Germany).

For electron microscopy, the collected VEC were washed in PBS containing 0.15% glycine, embedded in 12% gelatin, infiltrated with 2.3 M sucrose and frozen in liquid nitrogen.^[@ref27]^ Freeze substitution (FS) was carried out in 100% methanol containing 1% uranyl acetate following previously described methods.^[@ref32]^ An AFS2 FS device (Leica Microsystems Inc.) warmed the frozen VEC to −80 °C, and then to −60 °C for infiltration with Lowicryl HM20 resin (EMS, Hatfield, PA). The Lowicryl HM20 resin containing the VEC was polymerized with UV light at −50 °C.

60 nm thin sections of VEC were immunolabeled using the same polyclonal antibody against the nucleoside transporter CNT3 as was used for light microscopy, and 10 nm protein A gold, (PAG10, Utrecht University, The Netherlands). Dilutions of immunoreagents with 2% BSA in PBS were made at 1:25 and 1:50 for SLC28A3 and PAG10, respectively. The immunolabeling protocol followed established iterative methods^[@ref27]^ where the grids, section side down, were floated on drops of immunoreagents in a humidity chamber. Immunolabeled sections were contrasted using aqueous uranyl and lead stains. Imaging was performed using a Zeiss EM10C transmission electron microscope operating at 80 kVa. For counting, sections were imaged at a magnification of 400,000×.

Quantification {#sec5.4}
--------------

Sections from volunteer OCIS-02A-037 were collected on two separate grids and labeled simultaneously on two different days. The labeling distribution on each of the two labeled grids were compared. Previously described quantification methods to obtain estimates of "pool size"^[@ref9]^ were applied by counting approximately two hundred gold particles per grid for a total of four grids among six cellular compartments (plasma membrane, keratin, cytoplasm, microvilli, unknown intracellular, background). Antigen distributions were obtained from random arrays of micrographs, which were scanned to identify PAG10 particles and assign them to one of the six cellular compartments. Systematic random sampling approaches^[@ref9],[@ref33]^ were applied to eliminate selective bias. To test for reproducible patterns of labeling, the Pearson correlation coefficient (*r*)^[@ref9]^ was calculated between two sets of two grids. The χ^2^ test was used to test the null hypothesis of uniform labeling across the grids. The χ^2^ test was performed as previously described.^[@ref9]^

Images of cells labeled with anti-CNT3 from volunteer OCIS-02A-025 were collected from anti-CNT3-labeled regions and from regions of plasma membrane on the same cells where there were no microvilli, and therefore, reduced labeling. The two regions were designated apical (with microvilli) and basolateral (no microvilli). Images were quantified using cross-lattice overlays to enable point counting to be performed. Gold labeling per micron length of membrane was estimated using established protocols.^[@ref34]^ Gold particle labeling on membranes was divided between particles closer than 3 nm to the membrane, and particles 3 and 5 nm from the membrane.

The Supporting Information is available free of charge at [https://pubs.acs.org/doi/10.1021/acsomega.0c02329](https://pubs.acs.org/doi/10.1021/acsomega.0c02329?goto=supporting-info).Triton X-100 control. This experiment demonstrates the cytoplasmic location of the CNT3 peptide recognized by the anti-CNT3 antibodies. Cultured V19 cells were preserved in formalin and labeled with anti-CNT3 antibodies followed by Cy3 conjugated secondary antibodies (red). Cells were visualized with FITC-concanavalin A (green) and DAPI (blue). Intact labeled cells, which were not Triton X-100 treated showed only weak label with the anti-CNT3 antibodies. Concanavalin A (green) labeled the cell periphery but did not penetrate the cell. Cells treated with Triton X-100 to give access to intracellular components show CNT3 label (red) and intracellular concanavalin A label (green). Scale bar = 20 μm; CNT3 antibodies label apical microvilli on polarized human VEC. Electron micrographs of sections through VEC labeled with anti-CNT3 antibodies and 10 nm protein A gold (PAG10). Most of the PAG10 label was over cytoplasmic regions of the microvilli. The PAG10 labeling is associated with microvilli on one side of the cell (apical microvilli). The membrane on the opposite side of the cell has no microvilli and few PAG10 particles. A different cell has CNT3 labeling over the apical microvilli (arrows). In this image a 100 nm scale bar has been added to illustrate the dimensions of the apical microvilli. Some gold labeling is associated with a keratin bundle (arrowhead). An extracellular bacterium is also present in the image. The VEC was from an African American female in her mid 30s (OCIS-02A-025). Scale bars = 0.5 μm; and Sequential sections labeled with anti-CNT3 antibodies and PAG10. Two sequential sections through VEC from an African American female in her mid 30s (OCIS-02A-025) labeled with anti-CNT3 antibodies and PAG10. The 60 nm thick sections, 180 nm apart, show the variability of antibody labeling over the same region of one cell. Microvilli on the cell membrane have many gold particles associated with them. Microvilli in the same region of the cell have fewer gold particles. Extracellular bacteria assist in matching the same region on the two sections. Scale bar = 0.5 μm. ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c02329/suppl_file/ao0c02329_si_001.pdf))
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BSA

:   bovine serum albumin

CLSM

:   confocal laser scanning microscopy

CNT3

:   human concentrative nucleoside transporter 3

DABCO

:   1,4-diazabicyclo\[2.2.2\]octane

DAPI

:   4′,6-diamidino-2-phenylindole

IgG

:   immunoglobulin G

PAG10

:   10 nm sized protein A-gold

PBS

:   phosphate buffered saline

PrEP

:   pre-exposure prophylaxis

SLC

:   solute carrier

SLC28A3

:   gene for the human concentrative nucleoside transporter 3

TEM

:   transmission electron microscopy

VEC

:   vaginal epithelial cell(s)
